Denali Therapeutics Q2 2024 GAAP EPS $(0.59) Beats $(0.68) Estimate, Cash Balance Of Approximately $1.35B
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics reported a Q2 2024 GAAP EPS of $(0.59), beating the estimate of $(0.68). The company also reported a cash balance of approximately $1.35 billion.
August 01, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics reported a Q2 2024 GAAP EPS of $(0.59), beating the estimate of $(0.68). The company also reported a cash balance of approximately $1.35 billion.
Denali Therapeutics' better-than-expected EPS and strong cash balance are positive indicators for the company's financial health, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100